GUT MICROBIAL METABOLISM OF 5-ASA DIMINISHES ITS CLINICAL EFFICACY IN IBD

被引：0
|
作者：
Mehta, Raaj S.
Mayers, Jared
Glasser, Nathaniel
Zhang, Yancong
Bhosle, Amrisha
Nguyen, Long H.
Ma, Wenjie
Bae, Sena
Branck, Tobyn
Ananthakrishnan, Ashwin
Franzosa, Eric A.
Balskus, Emily
Chan, Andrew
Huttenhower, Curtis
机构：
来源：
GASTROENTEROLOGY | 2022年 / 162卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
549
引用
收藏
页码：S130 / S130
页数：1
相关论文
共 50 条
  • [41] Release of 5-ASA from Asacol appears independent of gut luminal pH in ulcerative colitis
    Nugent, S
    Rampton, D
    Obeid, O
    Evans, D
    Kumar, D
    GASTROENTEROLOGY, 2001, 120 (05) : A455 - A455
  • [42] Efficacy of Oral Mesalamine Monotherapy (5-ASA) versus Combination Oral Mesalamine Plus Proton Pump Inhibitor (5-ASA/PPI) Therapy in the Treatment of Ulcerative Colitis (UC)
    Lichtenstein, Gary
    Marchioni, Renee
    Blonski, Wojciech
    Mudireddy, Prashant
    Buchner, Anna
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S630 - S631
  • [43] A new oral delivery system for 5-ASA: Preliminary clinical findings for MMx
    Prantera, C
    Viscido, A
    Biancone, L
    Francavilla, A
    Giglio, L
    Campieri, M
    INFLAMMATORY BOWEL DISEASES, 2005, 11 (05) : 421 - 427
  • [44] Clinical trial of 5-aminosalicylic acid (5-ASA) in acute Shigella colitis.
    Bardhan, PK
    Islam, MR
    Islam, M
    Saha, D
    GASTROENTEROLOGY, 1998, 114 (04) : A926 - A926
  • [45] Microproteinuria in patients with inflammatory bowel disease (IBD): Is it associated with the disease activity or the treatment with 5-aminosalicylic acid (5-ASA)?
    Poulou, A
    Goumas, K
    Dandakis, D
    Tyrmpas, I
    Panagiotaki, M
    Papatheodoridis, G
    Terzi, T
    Terzoglou, C
    Georgouli, A
    Liosis, I
    Soutos, D
    GASTROENTEROLOGY, 2004, 126 (04) : A469 - A469
  • [46] 5-Aminosalicylic acid (5-Asa) therapy is associated with a decreased risk of polyps in inflammatory bowel disease (IBD) patients
    Rubin, DT
    Terdiman, JP
    Blumentals, WA
    Ullman, T
    GASTROENTEROLOGY, 2005, 128 (04) : A571 - A571
  • [47] Does oral butyrate improve 5-ASA efficacy in ulcerative colitis? A randomized, controlled trial
    Vernia, P
    Monteleone, G
    Grandinetti, G
    Villotti, G
    Frieri, G
    Marcheggiano, A
    Pallone, F
    Caprilli, R
    Torsoli, A
    GASTROENTEROLOGY, 1997, 112 (04) : A1113 - A1113
  • [48] THERAPEUTIC EFFICACY OF 5-ASA MOLECULES IN INFLAMMATORY BOWEL-DISEASE - CRITICAL-REVIEW
    VANGOSSUM, A
    ACTA GASTRO-ENTEROLOGICA BELGICA, 1992, 55 (5-6): : 462 - 471
  • [49] 5-aminosalicylic acid (5-ASA) inhibits luminal sulfide production by gut bacteria in ulcerative colitis.
    Pitcher, MCL
    Beatty, ER
    Cummings, JH
    GASTROENTEROLOGY, 1996, 110 (04) : A992 - A992
  • [50] 5-AMINOSALICYLIC ACID (5-ASA) RETENTION ENEMATA FOR LONG-TERM THERAPY OF INFLAMMATORY BOWEL-DISEASE (IBD)
    WYMAN, JB
    NUNEZ, JF
    PARENT, K
    NORFLEET, RG
    KIRCHNER, JP
    RYAN, ME
    RHODES, RA
    GASTROENTEROLOGY, 1985, 88 (05) : 1636 - 1636
12345